Why the study?
Does Danshen protect against adriamycin-induced cardiac and hepatic toxicity in Wistar rats?
Population
Wistar rats (n=75)
Comparison
Danshen 20 mg/kg or 100 mg/kg orally for 30… vs Adriamycin alone, or saline control
Design
Preclinical
Follow-up
30 days
Authors
Loading...
Clinical use of Danshen for ADR toxicity unsupported; leaves open translation from rat cardioprotection data.
Does Danshen protect against adriamycin-induced cardiac and hepatic toxicity in Wistar rats?
Danshen demonstrates potential protective effects against adriamycin-induced cardiotoxicity and hepatotoxicity in a preclinical rat model.
You et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: